The neuron is a highly polarized cell from which characteristically long processes, the axons and dendrites, extend. In these processes, the neuronal cytoskeleton acts as a dynamic scaffold composed of longitudinally arranged neurofilaments (NFs)^1^ and microtubules (MTs). MTs tend to form fascicles in which various kinds of crossbridge structures have been observed ([@B18]; [@B20]).

Microtubule-associated proteins (MAPs), a group of filamentous proteins such as microtubule-associated protein 1B (MAP1B), MAP1A, MAP2, and tau, have been demonstrated to be components of these extensive crossbridge structures associated with MTs ([@B20], 1988*a*,*b*; [@B35],[@B36]; [@B33]; [@B19]). Considerable evidence supports the hypothesis that MAPs play a crucial role in neuronal morphogenesis. In fact, cDNA transfection studies have revealed that tau and MAP2 induce elongation of processes of nonneuronal cells, such as fibroblasts and Sf9 cells, and formation of MT bundles ([@B23], [@B26]; [@B24], [@B7]).

MAP1B, a major component of the neuronal cytoskeleton ([@B3], 1985), which is also known as MAP1.2 ([@B14]), MAP1x ([@B6]), and MAP5 ([@B31]), forms long crossbridges between MTs ([@B20]; [@B33]). MAP1B is encoded by a single-copy gene ([@B13]), the product of which is proteolytically processed to a heavy chain and light chain 1 (LC1), which are assembled with LC2 and LC3 to form a complex MT-binding domain ([@B48]; [@B15]). MAP1B is mainly expressed in neurons, though it exists in other cell types as well ([@B12]; [@B50]; [@B47]). MAP1B is expressed at high levels in the immature nervous system, and its level of expression declines in parallel with neuronal differentiation ([@B4]; [@B25], [@B31]; [@B32]; [@B34]; [@B45]; [@B13]). In the adult nervous system, MAP1B continues to be expressed in localized brain areas, for example in olfactory nerve axons ([@B49]) and retinal photosensitive cells ([@B43]) where axonal elongation continues. Phosphorylation of MAP1B is also under strong developmental control; that is, the level of mode I phosphorylation catalyzed by proline-directed protein kinases decreases during development, but that of mode II phosphorylation catalyzed by casein kinase II is maintained in the mature nervous system ([@B1]). Furthermore, several lines of in vitro evidence suggest that MAP1B plays a role in neurite extension. Depletion of casein kinase II, which is thought to catalyze phosphorylation of MAP1B ([@B9]), blocked neuritogenesis of mouse neuroblastoma cells ([@B46]), and attenuation of MAP1B expression by antisense oligonucleotide treatment resulted in inhibition of neurite extension of NGF-treated PC12 cells ([@B5]). However, the function of MAP1B in vivo is still largely unknown.

To define the function of MAP1B in vivo, we have disrupted the MAP1B gene by homologous recombination in embryonic stem (ES) cells and used these mutant cells to generate mutant mice with a disrupted MAP1B allele (R21). Mouse lines with mutations in the MAP1B gene have been previously described (Map1b571) ([@B11]), the phenotypes of which are very different from those of R21. [@B11] reported that Map1b571 embryos homozygous for the mutated MAP1B gene died before reaching 8-d embryos, and Map1b571 heterozygotes showed severely abnormal phenotypes such as motor dysfunction, vast histological abnormalities, lack of visual acuity, and premature mortality. However, in our study, R21 heterozygotes exhibited no overt abnormalities in their development and behavior. The size of the adult R21 homozygous mutant brain was slightly reduced and EM analysis revealed delayed development of the R21 homozygous mutant nervous system, though histological abnormalities reported by [@B11], such as abnormal morphology of the cerebellar Purkinje cells, were not observed. A long truncated peptide produced by Map1b571 mutants is considered to act in a dominant-negative fashion, resulting in their abnormally severe phenotypes, because the predicted truncated product of the genes as disrupted in the previous study is very long (571 amino acids), and Map1b571 heterozygotes whose level of MAP1B expression remained at about half of the level of controls have more severe neuronal abnormalities than R21 homozygotes. On the other hand, our findings suggest that MAP1B plays an important role in neuronal morphogenesis in cooperation with other neuronal MAPs, representing a MAP1B loss of function effect.

Materials and Methods
=====================

Construction of MAP1B Targeting Vector
--------------------------------------

For disruption of the endogenous MAP1B gene, a replacement-type targeting vector was constructed (Fig. [1](#F1){ref-type="fig"} *A*). A SalI-SalI fragment (13.5 kb) containing the first coding exon of the MAP1B gene was obtained from the 129/Sv mouse genomic library and subcloned into pBluescript II. Part of the genomic sequence of the clone was confirmed to be identical to the sequence of MAP1B cDNA ([@B28]). The PGK-neo gene was ligated between the XhoI site introduced into the first coding exon by mutagenesis using PCR and a HindIII site downstream of the first coding exon. The PGK-tk gene was ligated into the upstream polylinker site.

Targeting the MAP1B Gene in ES Cells
------------------------------------

Linearized vector-1 was electroporated into cultured J1 cells, and transformants were selected using G418 and FIAU as described elsewhere ([@B17]). The G418- and FIAU-resistant colonies were expanded into cell lines, and genomic DNA was isolated for Southern blotting. Homologous recombination was detected using BamHI with a "probe," a genomic region that was not included in the recombination constructs, and then confirmed using EcoRI digestion (Fig. [1](#F1){ref-type="fig"} *A*) for detection of the presence of a mutated MAP1B gene. In addition, neo-probe was used for hybridization, and single bands that migrated to the expected positions were observed in lanes loaded with genomic DNA isolated from homologous recombinants.

Genotyping of Animals
---------------------

Two separate allele-specific PCRs were performed for each animal. The following primers were synthesized and used for the PCRs: primer 1, 5′-ACACTTCTCTCAGGCTTGAGCAGAGCCG-3′; primer 2, 5′-ACGATCGGATCCCCAGCTCGATGTTG-3′; and primer 3, 5′-GCTAAAGCGCATGCTCCAGACTGCCTTG-3′. The product amplified using primers 1 and 2 was generated from the wild-type allele, whereas the product amplified using primers 1 and 3 was generated from the mutated allele (Fig. [1](#F1){ref-type="fig"} *A*). DNA samples were prepared by incubating tails of animals in PCR buffer containing 50 mM KCl, 15 mM Tris-Cl, pH 8.3, 2.5 mM MgCl~2~, 0.5% Tween 20, and 100 μg/ml proteinase K at 55°C for 1 h, followed by inactivation of the proteinase K at 95°C for 10 min. PCR amplifications consisted of denaturation at 94°C (30 s), annealing at 65°C (30 s), and extension at 72°C (30 s) for 35 cycles, in a reaction buffer containing 10 mM Tris-Cl, pH 8.3, 50 mM KCl, 2.0 mM MgCl~2~, 200 μM each of dATP, dCTP, dGTP, and dTTP, 1 μM each of PCR primers, and 1 U of Taq DNA polymerase (Perkin-Elmer Corp., Norwalk, CT). An aliquot of each PCR mixture was analyzed by agarose gel electrophoresis.

Preparation of Crude Extracts and Immunoblotting
------------------------------------------------

Crude extracts of whole brain were obtained as described previously ([@B39]). Equal amounts of crude extracts were separated by PAGE. Proteins were then electrophoretically transferred to nylon filters (Millipore Corp., Bedford, MA). The nylon filters with transferred proteins were blocked with 2% skim milk in TBS, incubated with mAbs or polyclonal antisera for 1 h, and then rinsed in TBS containing 0.05% Tween 20. In the case of the polyclonal antisera, mouse anti--rabbit IgG was reacted with primary Abs. Finally, the nylon filters were incubated with ^125^I-labeled protein A. Binding was detected and quantified by autoradiography using an imaging analyzer (model BAS-2000; Fuji Film, Tokyo, Japan). The signals were normalized for the signal obtained with an anti--NF-M Ab as an internal control. For the primary Abs, the following mAbs or polyclonal antisera were used: 3d2 and YXY ([@B28]; kindly provided by N.J. Cowan, New York University Medical Center) for MAP1B; tau-1 (Boehringer Mannheim Corp., Indianapolis, IN), anti--human tau, and 5E2 (kindly provided by Y. Ihara, University of Tokyo) for tau; HM2 (Sigma Chemical Co., St. Louis, MO) for MAP2; 1D1 ([@B35]) for MAP1A; and NN18 (Sigma Chemical Co.) for NF-M.

Histological and Anatomical Analysis
------------------------------------

Mice matched by age were anesthetized with ether and fixed in 4% paraformaldehyde. Fixed brain tissues were embedded in paraffin, sectioned, and stained with hematoxylin-eosin.

For immunocytochemical analysis, mice anesthetized with ether were perfused with 2% paraformaldehyde and 0.1% glutaraldehyde in phosphate buffer. Various parts of the brains (cerebellum, hippocampus, olfactory bulb, spinal cord, and retina) were dissected out and stored in the same fixative overnight at 4°C. The procedure for cryoprotection, freezing, and sectioning was previously described ([@B16]). After preincubation in PBS containing glycine to quench aldehydes, followed by 5% skim milk in PBS, the sections were allowed to react with the primary Abs followed by the secondary Abs (rhodamine-conjugated goat anti-- mouse or anti--rabbit IgG).

Conventional Electron Microscopy and Morphometric Analysis
----------------------------------------------------------

Mice matched by age were perfused with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Tissues were dissected out and fixed overnight, processed for the conventional EM, and viewed under an electron microscope (model 1200EX; JEOL U.S.A., Peabody, MA) at 100 kV. Matching areas of each tissue were examined and photographed, and then the numbers of axons with compacted myelin sheaths were directly counted from prints without preknowledge of genotypes. The diameters of both myelinated and unmyelinated axons were also measured. The numbers of myelinated axons were then converted to densities of myelinated axons by dividing the counts by areas excluding glial cells and blood vessels. In the same way, the MT numbers were counted and then converted to MT densities by dividing the MT count by the area of each axon.

Results
=======

Generation of Mice with Disrupted MAP1B Gene
--------------------------------------------

The analysis of G418-resistant ES clones revealed a targeting frequency of ∼1/250. ES cells carrying the mutated MAP1B gene were injected into C57BL/6 embryos at the blastocyst stage, and the embryos were then transferred into the uteri of pseudopregnant recipients. The embryos injected with R21 cell line developed into chimeric mice transmitting the ES cell genome through the germ line, as indicated by the agouti coat color of the offspring of matings of the chimeric mice with C57BL/6 females. Approximately 50% of these agouti pups were heterozygous for the mutant MAP1B allele as determined by PCR and Southern blot analysis (data not shown). These mice were indistinguishable from their wild-type littermates and displayed no discernible abnormalities. To investigate the phenotype of homozygous mutant mice, we interbred heterozygous mutant mice and genotyped the offspring (Fig. [1](#F1){ref-type="fig"} *B*). The predicted 1:2:1 Mendelian distribution of wild-type (MAP1B+/+), heterozygous mutant (MAP1B+/−), and homozygous mutant (MAP1B−/−) animals was found.

A schematic direct comparison of our targeting strategy with that of [@B11] is presented in Fig. [2](#F2){ref-type="fig"}. The predicted truncated product of the genes as disrupted by us is 11 amino acids long (Fig. [2](#F2){ref-type="fig"} *C*), whereas that of the genes disrupted by [@B11] is 571 amino acids long (Fig. [2](#F2){ref-type="fig"} *B*).

General Observations
--------------------

MAP1B+/− mice grew with no apparent abnormalities in a normal cage environment. Their bodies and entire brains developed and reached normal weight (Tables [I](#TI){ref-type="table"} and [II](#TII){ref-type="table"}). Their behavior could not be distinguished from that of MAP1B+/+ littermates. On the other hand, the bodies and mature whole brains of the MAP1B−/− mice were significantly smaller than those of the MAP1B+/+ mice (Tables [I](#TI){ref-type="table"} and [II](#TII){ref-type="table"}). However, severe motor dysfunctions reported by [@B11], such as gait ataxia, spastic tremor, and limb paralysis, were not observed in our MAP1B−/− mice. Their eyes often looked a little smaller than those of the wild-type mice, possibly because of slight drooping of their upper eyelids and retraction of their eyeballs (blepharoptosis-like symptom). We confirmed that the size of their eyeballs was within the normal range. More than half of the MAP1B−/− mice exhibited this symptom unilaterally or bilaterally (Table [III](#TIII){ref-type="table"}). Since [@B11] reported that mice heterozygous for a disrupted MAP1B gene lacked visual acuity, we subjected adult mutant mice to a Morris swimming navigation test with visible cues ([@B27]) to determine whether they had visual acuity. MAP1B−/− mice with the blepharoptosis-like symptom could find the platform using the visual cues, and their levels of performance did not differ from those of MAP1B+/+ mice (data not shown); therefore, we concluded that they are not blind. Only a small number of MAP1B−/− mice (\<5% of the total number of MAP1B−/− mice) did not gain weight and died before reaching 3 wk of age. However, once the MAP1B−/− mice reached adulthood, they showed no evidence of premature mortality.

Expression of Cytoskeletal Proteins in MAP1B−/− Mutant Mice
-----------------------------------------------------------

For examination of the effect of the disruption of the MAP1B gene, crude extracts were prepared from whole brain (cerebrum and cerebellum) and examined by immunoblotting with anti-MAP1B antisera 3d2 and YXY ([@B28]; kindly provided by N.J. Cowan), and anti-MAP1B mAb 1B6 ([@B33]). 3d2 and YXY recognize the entire MAP1B population, while 1B6 reacts only with phosphorylated MAP1B. 3d2 reacts with repeat motifs near the NH~2~ terminus, which is responsible for the interaction between MAP1B and MTs, and YXY reacts with COOH-terminal--imperfect repeats (Fig. [2](#F2){ref-type="fig"} *A*). Abs stained very faintly a band of protein at a position slightly below that of MAP1B in MAP1B−/− crude brain extract blots (Fig. [3](#F3){ref-type="fig"}, *A* and *B*). We quantified this faint band using 3d2 and YXY. The amount of this faint immunoreactivity in MAP1B−/− brain is equivalent to 0--5% of that in MAP1B+/+ brain at postnatal days 4, 8, and 14 and postnatal week 15. This residual signal may be derived from a peptide different from the authentic MAP1B protein or a previously unknown alternatively spliced form.

It has been suggested that a functional redundancy might exist among MAPs ([@B17]; [@B10]). We measured the relative amounts of other MAPs in MAP1B−/− brains compared with those in MAP1B+/+ brains to investigate whether other MAPs are upregulated to compensate for the loss of functions of MAP1B. However, in postnatal day 4 and adult brains, the amounts of tau, MAP2 (a and b), and MAP1A did not differ between MAP1B−/− and +/+ mice (Fig. [3](#F3){ref-type="fig"}, *C--E*).

Brain Architecture in the Mutant Mice
-------------------------------------

It has been speculated that MAP1B plays important roles in neuronal morphogenesis, especially in neurite extension ([@B5]; [@B46]; [@B1]). In fact, Map1b571 heterozygotes have histological abnormalities in the cerebellum, olfactory bulb, hippocampus, and retina ([@B11]). To assess possible structural defects in the nervous system of MAP1B mutants, we examined tissue sections by light microscopy. The general structure of the MAP1B−/− mutant brains appeared normal in hematoxylin-eosin sections except that the size of the entire brains was slightly reduced (Table [II](#TII){ref-type="table"}). To compare the localizations of cytoskeletal proteins in mutant and control mice, we stained frozen sections of cerebellum from postnatal day 8 and adult brains with Abs against cytoskeletal proteins. The staining intensity with the anti-MAP1B antiserum YXY was much weaker in mutant sections than in control sections, while we found no difference between mutant and control sections in the staining pattern and intensity with anti-MAP1A, anti-MAP2, or anti-tau. The dendritic arborization and the shape of the somata of cerebellar Purkinje cells were within the normal ranges (Fig. [4](#F4){ref-type="fig"}, *A* and *B*). We examined other brain structures, i.e., the hippocampus, retina (Fig. [4](#F4){ref-type="fig"}, *C* and *D*), olfactory bulb, and spinal cord, of postnatal day 8 and adult brains immunohistochemically but found no abnormalities in the structure of the MAP1B−/− nervous system.

Delayed Myelination of MAP1B−/− Nervous System
----------------------------------------------

We focused on two representative structures in which MAP1B is expressed at high levels, the developing optic nerve and spinal cord ([@B42], [@B43]; [@B44]; [@B2]; [@B30]). We observed axons in optic nerves and anterior pyramidal tracts by EM and performed morphometric analyses. Since in the rodent optic nerve the ensheathment of axons occurs in a rostro-caudal gradient, that is, from eye to optic chiasm ([@B37]), we set three levels (A, B, and C) along the optic-nerve axis (Fig. [5](#F5){ref-type="fig"} *A*). At postnatal day 8, the densities of axons with compacted myelin sheaths were significantly decreased in sections of MAP1B−/− optic nerves (Figs. [5](#F5){ref-type="fig"} *B* and [6](#F6){ref-type="fig"}, *A* and *B*) and spinal cords (Fig. [7](#F7){ref-type="fig"} *A*). In the wild-type optic nerves, the level of myelination exhibited an overt rostro-caudal gradient as expected, but no such gradient was apparent in the MAP1B−/− optic nerves (Fig. [5](#F5){ref-type="fig"} *B*). Next, we observed axons of adult MAP1B−/− mice. The densities of axons with compacted myelin sheaths did not differ between the adult MAP1B−/− and +/+ mice in optic nerve sections (Figs. [5](#F5){ref-type="fig"}, *C* and *D* and [8](#F8){ref-type="fig"}, *A* and *B*) and in spinal cord sections (Fig. [7](#F7){ref-type="fig"} *B*). We concluded that the myelination of MAP1B−/− axons in optic nerves and anterior pyramidal tracts of spinal cords was significantly delayed at postnatal day 8, but caught up with wild-type myelination during development and was almost complete in the adult mice. We found no difference in the level of myelination between MAP1B−/− and +/+ trigeminal and sciatic nerves at postnatal day 8 (data not shown).

Axonal Diameters in MAP1B−/− Optic Nerve
----------------------------------------

To assess whether axonal maturation is delayed in MAP1B−/− neurons, we measured diameters of MAP1B−/− axons in sections of juvenile and adult optic nerves. At postnatal day 8, the diameters of axons were significantly decreased in MAP1B−/− sections (Fig. [9](#F9){ref-type="fig"} *A*). However, the axonal diameter did not differ between MAP1B−/− and +/+ optic nerves at postnatal week 8 (Fig. [9](#F9){ref-type="fig"} *B*, *P* \>0.6; Student\'s *t* test). This indicates that axonal maturation was delayed in MAP1B−/− optic nerves, but caught up with that in wild-type optic nerves during development.

MT Density in MAP1B−/− Axons
----------------------------

MAP1B has been postulated to regulate MT dynamics via an MT-stabilizing effect in cooperation with MAP2, tau, and MAP1A ([@B40]). In mice lacking tau, neurons exhibit neurite elongation but decreased densities of MTs in small-caliber axons ([@B17]). This decreased MT density has been attributed to the loss of an MT-stabilizing effect of tau, though neurons lacking tau show axon elongation, possibly because of compensation by other MAPs for the loss of tau functions.

To assess whether the disruption of the MAP1B gene affects MT stability, we performed morphometric analysis of three representative structures: olfactory sensory neurons, in which MAP1B is strongly expressed even in the adult nervous system ([@B45]; [@B49]), the optic nerve, and cerebellar parallel fibers. No significant reduction of MT number and density was observed in MAP1B−/− axons of each area (Table [IV](#TIV){ref-type="table"}).

Discussion
==========

Delayed Development of MAP1B−/− Nervous System
----------------------------------------------

MAP1B is one of the early MAPs expressed mainly in the nervous system ([@B41]; [@B1]). It had been postulated that MAP1B is involved in neuronal morphogenesis ([@B5]; [@B46]; [@B1]). However, little is known about its physiological function. To define its role in vivo, we generated a mutant mouse line with a disrupted MAP1B gene. Though the weight of the MAP1B−/− brains was slightly reduced, their structures were not significantly different from those of MAP1B+/+ brains at the light microscopic level. EM analysis revealed that myelination and axon caliber expansion were delayed in developing MAP1B−/− optic nerves. However, we found no morphological differences between adult MAP1B+/+ and −/− optic nerve sections. These findings indicate that the development of the MAP1B−/− optic nerves was not completely inhibited by the disruption of the MAP1B gene, but delayed, and then caught up with that of the wild-type optic nerves. The same pattern of delayed myelination as found in MAP1B−/− optic nerve axons was observed in MAP1B−/− pyramidal tract axons.

What is the basis for this delay? The most plausible possibility is that MAP1B deficiency caused delayed axonal development, which would result in retardation of myelination because neurons associate specifically with oligodendrocytes and influence their development and differentiation via soluble factors ([@B8]). This hypothesis is consistent with the aforementioned reports suggesting an important role of MAP1B in neuronal morphogenesis. Another possibility is that oligodendrocytes themselves did not develop normally because of a lack of MAP1B. A considerable amount of MAP1B is normally expressed in oligodendrocytes ([@B12]; [@B50]; [@B47]). Furthermore, MAP1B expression is first detected in cultured glial progenitor cells immediately before they differentiate into complex process-bearing oligodendrocytes ([@B50]), suggesting that MAP1B might have a role in the formation of myelin-forming processes. Therefore, it is plausible that lack of MAP1B directly affects oligodendrocyte development, resulting in delayed myelination, which can disturb neuronal/axonal development. Since these two possibilities are compatible with each other, both mechanisms could be involved in the observed developmental delay of the MAP1B−/− nervous system.

On the other hand, why was the delayed myelination not observed in MAP1B−/− sciatic and trigeminal nerves at postnatal day 8? A possible explanation is that the myelination of the MAP1B−/− sciatic and trigeminal nerves had already caught up with that of the wild-type ones by the time of sacrifice of the mice. In rodents, myelination begins, peaks, and declines to a basal level at an earlier age in the peripheral nervous system than in the central nervous system ([@B38]), which supports this hypothesis. A second possibility is that the degree of the effect of MAP1B gene disruption differs between oligodendrocytes and Schwann cells. However, no data supporting this hypothesis are available.

Density of MTs in MAP1B−/− Mice
-------------------------------

In a previous study, we found a decreased number and density of MTs in cerebellar parallel fibers of tau-deficient mice, which could be attributed to loss of a MT-stabilizing effect of tau ([@B17]). The decrease in the density of MTs in the tau-deficient mice was specific to cerebellar small-caliber axons. Since in these axons tau accounts for a large proportion of the total MAPs, the loss of tau in these axons is considered to affect strongly the stability of MTs in these axons. However, disruption of the MAP1B gene resulted in no change in the density of MTs in the axons. Differences between MAP1B and other MAPs in regard to interactions with MTs might explain this difference in phenotypes between tau and MAP1B knock-out mice. First, in vitro assembly of MTs mediated by MAP1B is not as efficient as that mediated by other neuronal MAPs ([@B4]). Second, the MTs in fibroblasts transfected with MAP1B cDNA are less stable to the effects of an MT-depolymerization reagent than those in fibroblasts transfected with MAP2c or tau cDNA, with no extensive reorganization of MTs such as bundle formation, which is seen in fibroblasts transfected with tau or MAP2c cDNA ([@B40]). The fact that the MT density was unchanged in the MAP1B−/− axons might have been due to the weakness of the interaction of MAP1B with MTs. However, double knock-out mice generated by intercrossing tau and MAP1B knock-out mice exhibited decreased MT densities in the optic nerve and olfactory bulb (Inomata, S., unpublished observation). This suggests that disruption of the MAP1B gene enhances the effect of disruption of the tau locus to reduce the density of MTs. Taken together with a recent report that MAP1B and tau can be functionally substituted for each other in laminin-enhanced axonal growth of cultured cerebellar macroneurons ([@B10]), it is plausible that MAP1B functions to stabilize neuronal MTs in cooperation with other MAPs.

Phenotypes of MAP1B−/− Mutants
------------------------------

The phenotypes of our MAP1B mutants (R21 mutant mice) are very different from those of Map1b571 mutant mice ([@B11]), mainly in the following points: (*a*) Map1b571 heterozygotes showed severe neuronal abnormalities, but R21 heterozygotes appeared healthy. (*b*) Map1b571 homozygous mutant embryos were nonviable, but R21 homozygotes reached adulthood. Generally, Map1b571 mutant mice exhibited more severe abnormalities than R21 mutant mice. This phenotypic variation cannot be attributed to differences in genetic background, as both R21 and Map1b571 mutant mice were analyzed in the same hybrid C57BL/129 backgrounds.

Our targeting scheme and that of [@B11] differ most considerably in the design of the targeting vectors; we inserted a selection cassette into the first coding exon of the MAP1B gene, whereas [@B11] inserted it into a SpeI site 5′ to the MT-binding domain of the MAP1B gene (Fig. [2](#F2){ref-type="fig"}). It is reasonable to consider that this difference in vector construction is at the basis of the phenotypic variation. The predicted truncated product of the gene as disrupted by [@B11] is 571 amino acids long, whereas that of the gene as disrupted by us is 11 amino acids long (Fig. [2](#F2){ref-type="fig"}, *B* and *C*). The phenotypes of Map1b571 heterozygotes cannot be explained by a simple loss of function of the MAP1B gene because Map1b571 heterozygotes, in which the amount of MAP1B remained at about half the amount in the wild-type mice, have a more severe phenotype than do R21 homozygotes. Therefore, the most plausible possibility is that Map1b571 mutant mice produce a long truncated peptide acting in a dominant-negative fashion, resulting in their abnormally severe phenotypes. By immunoblotting using an Ab specific for the NH~2~-terminal 150 amino acids of MAP1B, [@B11] have excluded the existence of this long truncated product in their mutant mice, and they speculated that this product is unstable. However, judging from the pattern of the blottings they presented, they used mature brain tissue for immunoblotting, not developing brain tissue, though they did not clearly state the ages of mice sacrificed for their experiments. Therefore, considering that MAP1B is strongly expressed in the developing murine nervous system, the existence of such a long truncated polypeptide in juvenile Map1b571 mutant brains cannot be excluded. Moreover, the phenotypes of Map1b571 mutant mice seem to be too severe, since mice lacking another major neuronal MAP, tau, resulted in only minimal neuronal phenotypes ([@B17]), and even double knock-out mice lacking both tau and MAP1B could reach adulthood (unpublished observation). From the above, we conclude that R21 mutant mice exhibit a true loss of function phenotype of the MAP1B gene, whereas the phenotypes of Map1b571 mutant mice are affected by a long truncated product acting in a dominant-negative fashion.

Another possibility is that "neighborhood phenotypic effects" ([@B29]) might contribute to the difference in phenotypes between R21 and Map1b571 mutant mice. This term refers to deletion of part of the target gene, or insertion of a selection cassette, affecting the expression of other genes located near the intended target, confounding the interpretation of phenotypes. Several cases of this effect mediating phenotypic variation due to mutations introduced by gene targeting have been described ([@B29]). In the case of myogenic regulatory factor 4, different laboratories have generated knock-outs with different phenotypes, ranging from death at birth to survival to adulthood ([@B29]). For determination of whether this is the case with MAP1B knock-outs, details of the structure of neighboring genes must be elucidated, and mice with subtle mutations in the MAP1B gene, such as an effectively positioned stop codon, must be generated.

From the above, we conclude that MAP1B plays an important role in neuronal development. However, the exact functions of MAP1B in vivo remain obscure. Future analysis of tau/MAP1B double mutant and primary neuronal cultures derived from various mutants will enrich our understanding of the functions of MAPs.
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![Targeted disruption of the MAP1B gene in ES cells and mice. (*A*) Targeting strategy: Wild-type allele containing the first coding exon of the MAP1B gene, replacement-type targeting vector, and targeted allele after homologous recombination are shown. *P1*, primer 1; *P2*, primer 2; *P3*, primer 3; *B*, BamHI; *E*, EcoRI; *H*, HindIII. Bar, 1 kb. (*B*) Genotype of F2 mice of R21 line. Tail DNA was isolated and analyzed by Southern blotting using the 5′-flanking probe (*A*, *probe*) after digestion with BamHI. Lane *1*, MAP1B−/− mouse; lane *2*, MAP1B+/− mouse; lane *3*, MAP1B+/+ mouse. *WT*, wild-type band; *HR*, homologous recombinant band.](JCB.32759f1){#F1}

![Comparison of our gene disruption strategy with that used by [@B11]. (*A*) MAP1B polyprotein. 3d2 and YXY, the regions to which two rabbit anti-MAP1B antisera bind, are shown. *LCBS*, light chain binding site; *MTBD*, microtubule-binding domain; *CTIR*, COOH-terminal imperfect repeats; *LC1*, light chain 1; *AA*, amino acids. (*B*) Predicted truncated product of the gene as disrupted by [@B11]. (*C*) Predicted truncated product of the gene as disrupted by us.](JCB.32759f2){#F2}

###### 

Body Weight of Mutant Mice and Wild-Type Controls

  Age[\*](#TFI-150){ref-type="table-fn"}      Sex         Mean weights ± SD (number of mice examined)                           
  ---------------------------------------- -- -------- -- --------------------------------------------- -- ----------------- -- ---------------------------------------------------
                                                                                                           *g*                  
  8 d                                                       5.1 ± 0.8 (28)                                  4.8 ± 0.9 (28)       3.7 ± 0.7 (17)[‡](#TFI-152){ref-type="table-fn"}
  8 wk                                        male        23.9 ± 2.7 (7)                                   25.0 ± 2.8 (18)      20.1 ± 2.6 (7)[§](#TFI-153){ref-type="table-fn"}
                                              female       19.2 ± 1.4 (13)                                 19.4 ± 2.5 (21)      16.0 ± 3.0 (7)[§](#TFI-153){ref-type="table-fn"}
  12 wk                                       male        26.9 ± 3.2 (7)                                   28.2 ± 3.8 (18)      21.2 ± 2.2 (7)[‖](#TFI-155){ref-type="table-fn"}
                                              female       22.0 ± 1.8 (10)                                 21.4 ± 2.9 (20)      17.9 ± 2.7 (5)[§](#TFI-153){ref-type="table-fn"}

 Number of postnatal days or weeks at time of measurements.  

 Different from value for wild-type mice at *P* \< 0.000001, at *P* \< 0.05, 

and at *P* \< 0.005. 

  Student\'s *t* test was used to determine the significance of the difference.  

###### 

Brain Weight of Mutant Mice and Wild-Type Controls

  Genotype          Weight (*n*)[\*](#TFII-150){ref-type="table-fn"}        Age[‡](#TFII-152){ref-type="table-fn"}
  -------------- -- ---------------------------------------------------- -- ----------------------------------------
                    *g*                                                     
  Wild-type         0.48 ± 0.02 (6)                                         137 ± 21
  Heterozygote      0.47 ± 0.03 (12)                                        136 ± 22
  Homozygote        0.41 ± 0.02 (7)[§](#TFII-153){ref-type="table-fn"}      136 ± 21

 Weight of whole brain (cerebrum + cerebellum). The means ± SD and *n* (the number of mice examined) are shown.  

 Number of postnatal days at time of sacrifice for experiments.  

 Different from value for wild-type mice at *P* \< 0.001; Student\'s *t* test was used to determine the significance of the difference.  

###### 

Blepharoptosis-like Symptom in MAP1B−/− Mice

  Symptom         *n* [\*](#TFIII-150){ref-type="table-fn"}
  ------------ -- -------------------------------------------
  Bilateral       3
  Unilateral      3
  No symptom      2
  Total           8

Number of mice examined 

![Immunoblot analysis of crude extracts of brain with the anti-MAP1B antiserum 3d2 (*A*), with the anti-MAP1B mAb 1B6 (*B*), with the anti-MAP2 mAb HM2 (*C*), with the anti-tau mAb tau-1 (*D*), and with the anti-MAP1A mAb 1D1 (*E*). (*A* and *B*) Lane *1*, MAP1B+/+ brain at postnatal day 4; lane *2*, MAP1B−/− mutant brain at postnatal day 4; lane *3*, MAP1B+/+ brain at postnatal week 8; lane *4*: MAP-1B−/− brain at postnatal week 8. *NF-M*, neurofilament M. (*C--E*) Lane *1*, MAP1B+/+ brain at postnatal week 8; lane *2*, MAP-1B−/− brain at postnatal week 8.](JCB.32759f3){#F3}

![(*A* and *B*) Immunofluorescence micrographs of adult cerebellum. Sagittal cryosections of cerebellar vermis of MAP1B+/+ (*A*) and −/− (*B*) mice were stained with anti-MAP1A mAb 1D1. (*C* and *D*) Paraffin sections of retinae of MAP1B+/+ (*C*) and −/− (*D*) mice stained with hematoxylin-eosin are shown. There are no morphological differences between the MAP1B+/+ and −/− tissues.](JCB.32759f4){#F4}

![(*A* and *C*) Schematic illustrations of optic nerve at postnatal day 8 (*A*) and postnatal week 8--14 (*C*), showing levels A, B, C, and D, at which ultrathin sections were taken for EM analysis. Each level was determined by the distance from the optic chiasm. (*B* and *D*) Quantitative comparison of the numbers of myelinated axons per unit area in juvenile (*B*) and adult (*D*) optic nerves of MAP1B+/+ and −/− mice. Solid bars represent each value (per 10^2^ μm^2^) for the optic nerve of a MAP1B+/+ mouse. Open bars represent each value (per 10^2^ μm^2^) for the optic nerve of a MAP1B−/− mouse. *PD*, postnatal days; *PW*, postnatal weeks.](JCB.32759f5){#F5}

![Electron micrographs showing representative areas of cross sections of optic nerves of MAP1B+/+ (*A*) and −/− (*B*) mice at postnatal day 8. Axons in the MAP1B−/− optic nerve (*B*) are less myelinated than those in the MAP1B+/+ optic nerve (*A*). Bar, 2 μm.](JCB.32759f6){#F6}

![Quantitative comparison of the numbers of myelinated axons (per 10^2^ μm^2^) in juvenile (*A*) and adult (*B*) anterior pyramidal tract axons of MAP1B+/+ and −/− spinal cords. Solid bars represent each value (per 10^2^ μm^2^) for the spinal cord of a MAP1B+/+ mouse. Open bars represent each value (per 10^2^ μm^2^) for the spinal cord of a MAP1B−/− mouse. *PD*, postnatal days; *PW*, postnatal weeks.](JCB.32759f7){#F7}

![Electron micrographs showing representative areas of cross sections of optic nerves of MAP1B+/+ (*A*) and −/− (*B*) mice at postnatal week 14. There are no differences in the number of myelinated axons per unit area, diameter of axons, thickness of myelin sheaths, and density of MTs. Bar, 500 nm.](JCB.32759f8){#F8}

###### 

Quantitative comparison of the axonal diameters in juvenile (*A*) and adult (*B*) optic nerves of MAP1B+/+ and −/− mice. Solid bars represent mean values ± SD (μm) for axons in a MAP1B+/+ mouse. Open bars represent mean values ± SD (μm) for axons in a MAP1B −/− mouse. \*Different from value for controls at *P* \< 0.0005, \*\* at *P* \< 10^−8^, and \*\*\* at *P* \< 10^−11^. Student\'s *t* test was used to determine the significance of the differences. Levels A, B, C, and D are determined in the same way as described in Fig. [5](#F5){ref-type="fig"} legend. *PD*, postnatal days; *PW*, postnatal weeks. *n*, the number of axons examined.

![](JCB.32759f9a)

![](JCB.32759f9b)

###### 

MT Density in MAP1B+/+ and −/− Axons

  Examined area                  Number and genotype of samples      Age[\*](#TFIV-150){ref-type="table-fn"}      Area of examined axons      MT density[‡](#TFIV-152){ref-type="table-fn"} (*n*)
  --------------------------- -- -------------------------------- -- ----------------------------------------- -- ------------------------ -- -----------------------------------------------------
                                                                                                                  *10^−2^ μm^2^*              
  Cerebellar parallel fiber      Wild-type 8                         24                                           0.020 ± 0.010               1.2 ± 0.5 (49)
                                 Homozygote 9                        24                                           0.021 ± 0.006               1.2 ± 0.4 (31)
                                                                                                                                              
  Optic nerve                    Wild-type 9                          8                                           0.32 ± 0.12                 0.6 ± 0.2 (26)
                                 Wild-type 10                         8                                           0.30 ± 0.11                 0.7 ± 0.2 (35)
                                 Homozygote 10                        8                                           0.34 ± 0.11                 0.7 ± 0.1 (30)
                                 Homozygote 11                        8                                           0.31 ± 0.13                 0.7 ± 0.2 (28)
                                                                                                                                              
  Olfactory sensory neuron       Wild-type 11                         7                                           0.022 ± 0.006               1.3 ± 0.4 (27)
   (near the surface)            Homozygote 12                        7                                           0.023 ± 0.005               1.3 ± 0.4 (22)
                                                                                                                                              
  Olfactory sensory neuron       Wild-type 12                         7                                           0.033 ± 0.007               0.8 ± 0.3 (26)
   (near the glomerular          Wild-type 13                         8                                           0.034 ± 0.007               1.2 ± 0.5 (10)
   layer)                        Wild-type 14                         8                                           0.035 ± 0.014               1.1 ± 0.4 (16)
                                 Homozygote 13                        7                                           0.037 ± 0.006               0.8 ± 0.2 (25)
                                 Homozygote 14                        8                                           0.036 ± 0.014               1.0 ± 0.4 (26)
                                 Homozygote 15                        8                                           0.037 ± 0.006               1.2 ± 0.3 (20)

The means ± SD and *n* (the number of axons examined) are shown. In each examined area, MT density did not differ significantly between MAP1B+/+ and −/− mice.  

 Number of postnatal weeks at time of sacrifice for experiments.  

 Number of MTs per 10^−2^ μm^2^.  
